
Short-lived antibody-mediated saliva immunity against SARS-CoV-2 after vaccination

Supplemental information:

Table of contents:

Supplementary Figures:	2
Supplementary Figure 1. Validation tests of antibodies in saliva against RBD from SARS-CoV-2 in	2
the Luminex assay	

Supplementary Figures:



Supplementary Figure 1. Validation tests of antibodies in saliva against RBD from SARS-CoV-2 in the Luminex assay. Boxplots showing the level of antibodies in Log10(Fluorescence Intensity [FI]) in convalescent individuals and infection-naïve individuals. SARS-CoV-2 infection was confirmed by a positive RT-PCR result. All samples were collected before vaccination. Levels of IgG antibodies (A), levels of IgA antibodies (B), and levels of IgM antibodies (C) in convalescent and infection-naïve individuals. The horizontal dotted line indicates the assay cutoff. The p-values have been calculated using a Mann-Whitney test. p<0.05 was considered significant.